About Carisma Therapeutics
Carisma Therapeutics is a company based in Philadelphia (United States) founded in 2016 by Michael Klichinsky. Carisma Therapeutics has raised $3.85 million across 5 funding rounds from investors including AbbVie, TPG and Penn Medicine. The company has 46 employees as of December 31, 2024. Carisma Therapeutics offers products and services including CAR-Macrophages. Carisma Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Philadelphia, United States
- Employees 46 as on 31 Dec, 2024
- Founders Michael Klichinsky
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Carisma Therapeutics, Inc.
-
Annual Revenue
$19.63 M (USD)31.59as on Dec 31, 2024
-
Net Profit
-$60.48 M (USD)30.39as on Dec 31, 2024
-
EBITDA
-$58.83 M (USD)26.89as on Dec 31, 2024
-
Total Equity Funding
$3.85 M (USD)
in 5 rounds
-
Latest Funding Round
$30 M (USD), Post-IPO
Sep 22, 2022
-
Investors
AbbVie
& 14 more
-
Employee Count
46
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Carisma Therapeutics
Carisma Therapeutics is a publicly listed company on the NASDAQ with ticker symbol CARM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Carisma Therapeutics
Carisma Therapeutics offers a comprehensive portfolio of products and services, including CAR-Macrophages.
Engineered cells to target and destroy tumors in cancer patients
People of Carisma Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Carisma Therapeutics
Carisma Therapeutics has successfully raised a total of $3.85M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Carisma Therapeutics
Carisma Therapeutics has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include AbbVie, TPG and Penn Medicine.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed and early-stage therapeutics companies are invested in by MRLV.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on healthcare startups
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Carisma Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Carisma Therapeutics
Investment portfolio details for Carisma Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Carisma Therapeutics
Detailed financials for Carisma Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Carisma Therapeutics Comparisons
Peer comparison for Carisma Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Carisma Therapeutics
Carisma Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Carisma Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Carisma Therapeutics
Complete news archive for Carisma Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Carisma Therapeutics
Carisma Therapeutics was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Carisma Therapeutics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Carisma Therapeutics is a funded company, having raised a total of $3.85M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Carisma Therapeutics is 46.
Annual revenue of Carisma Therapeutics is $19.63M as on Dec 31, 2024.
Carisma Therapeutics was founded in 2016 and is based in Philadelphia, United States. Patient-derived macrophages are genetically engineered to produce chimeric antigen receptor macrophages, known as CAR-M, within the biotechnology sector focused on oncology. Solid tumor indications are targeted, such as recurrent ovarian cancer and HER2-overexpressing malignancies. Research and development efforts emphasize innovative cellular therapies for these conditions.
Carisma Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Carisma Therapeutics offers CAR-Macrophages.
Yes, Carisma Therapeutics is publicly traded on NASDAQ under the ticker symbol CARM.
Carisma Therapeutics has 15 investors. Key investors include AbbVie, TPG, Penn Medicine, Livzon Pharmaceutical, and IP Group.
The ticker symbol of Carisma Therapeutics is CARM on NASDAQ.